Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Saihkay HN et al. | Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. | 2011 Jan-Feb | J Pharmacol Toxicol Methods | pmid:20646985 |
Brainard BM et al. | Effects of clopidogrel and aspirin on platelet aggregation, thromboxane production, and serotonin secretion in horses. | 2011 Jan-Feb | J. Vet. Intern. Med. | pmid:21143302 |
Sambu N et al. | Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. | 2011 | Heart | pmid:21795297 |
Spectre G et al. | Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. | 2011 | Thromb. Haemost. | pmid:21800009 |
Hoh CM et al. | Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. | 2011 | Am. J. Vet. Res. | pmid:21801060 |
Dalli E et al. | Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. | 2011 | Thromb. Res. | pmid:21737127 |
Gao F et al. | Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. | 2011 | Chin. Med. J. | pmid:21740787 |
Lukasik M et al. | Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. | 2011 | Thromb. Res. | pmid:21788065 |
Shen L et al. | In vivo oxidation, platelet activation and simultaneous occurrence of natural immunity in atherosclerosis-prone mice. | 2011 | Isr. Med. Assoc. J. | pmid:21845968 |
Bauer J et al. | Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. | 2011 | Biochem. Pharmacol. | pmid:20933508 |
Oates JC et al. | Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. | 2011 | Am. J. Med. Sci. | pmid:20924284 |
Grove EL et al. | Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. | 2011 | J. Thromb. Haemost. | pmid:20955349 |
Trostchansky A et al. | Nitroarachidonic acid, a novel peroxidase inhibitor of prostaglandin endoperoxide H synthases 1 and 2. | 2011 | J. Biol. Chem. | pmid:21266582 |
Trefiletti G et al. | 1-Phenyl-6,7-dihydroxy-isochroman suppresses lipopolysaccharide-induced pro-inflammatory mediator production in human monocytes. | 2011 | Br. J. Nutr. | pmid:21269535 |
Gremmel T et al. | Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. | 2011 | Platelets | pmid:21231857 |
Kuo HL et al. | NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry. | 2011 | Br. J. Pharmacol. | pmid:21232029 |
Kleinbongard P et al. | Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. | 2011 | Circ. Res. | pmid:21183739 |
Dimitrievska S et al. | Low thrombogenicity coating of nonwoven PET fiber structures for vascular grafts. | 2011 | Macromol Biosci | pmid:21259437 |
Ceprnja M et al. | Oxidative stress markers in patients with post-traumatic stress disorder. | 2011 | Coll Antropol | pmid:22397253 |
Toliopoulos IK et al. | Inhibition of platelet aggregation and immunomodulation of NK lymphocytes by administration of ascorbic acid. | 2011 | Indian J. Exp. Biol. | pmid:22403863 |